Daratumumab in Sensitized Kidney Transplantation: Potentials and Limitations of Experimental and Clinical Use
| العنوان: | Daratumumab in Sensitized Kidney Transplantation: Potentials and Limitations of Experimental and Clinical Use |
|---|---|
| المؤلفون: | Thibault Damy, Karim Belhadj, Brian Ezekian, Chantal Gautreau, Jaeberm Park, Vincent Audard, David Kheav, Jean Kwun, Marie Matignon, Bradley H. Collins, John S. Yi, Stuart J. Knechtle, Diane Bodez, Janghoon Yoon, Dong-Feng Chen, Alton B. Farris, Elsa Poullot, Philippe Grimbert, Mark D. Stegall, Miriam Manook, Laureline Faivre, Alyssa M. Bilewski, Dehbia Menouch, Soulef Guendouz |
| المصدر: | J Am Soc Nephrol |
| بيانات النشر: | Ovid Technologies (Wolters Kluwer Health), 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Adult, Graft Rejection, Male, 0301 basic medicine, Benzylamines, medicine.medical_specialty, medicine.drug_class, Urology, 030230 surgery, Plasma cell, CD38, Cyclams, Monoclonal antibody, T-Lymphocytes, Regulatory, 03 medical and health sciences, 0302 clinical medicine, HLA Antigens, Heterocyclic Compounds, Isoantibodies, Animals, Humans, Medicine, Kidney transplantation, biology, business.industry, Plerixafor, Antibody-Dependent Cell Cytotoxicity, Antibodies, Monoclonal, Daratumumab, General Medicine, medicine.disease, ADP-ribosyl Cyclase 1, Kidney Transplantation, Macaca mulatta, Transplantation, Basic Research, 030104 developmental biology, medicine.anatomical_structure, Nephrology, biology.protein, Antibody, business, medicine.drug |
| الوصف: | BACKGROUND: Donor-specific antibodies are associated with increased risk of antibody-mediated rejection and decreased allograft survival. Therefore, reducing the risk of these antibodies remains a clinical need in transplantation. Plasma cells are a logical target of therapy given their critical role in antibody production. METHODS: To target plasma cells, we treated sensitized rhesus macaques with daratumumab (anti-CD38 mAb). Before transplant, we sensitized eight macaques with two sequential skin grafts from MHC-mismatched donors; four of them were also desensitized with daratumumab and plerixafor (anti-CXCR4). We also treated two patients with daratumumab in the context of transplant. RESULTS: The animals treated with daratumumab had significantly reduced donor-specific antibody levels compared with untreated controls (57.9% versus 13% reduction; P |
| تدمد: | 1533-3450 1046-6673 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb8b47caca2a185f48d67aa6d4990731Test https://doi.org/10.1681/asn.2018121254Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....bb8b47caca2a185f48d67aa6d4990731 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15333450 10466673 |
|---|